{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:52:59Z","timestamp":1791593579602,"version":"4.3.4"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.nbd.2019.104569","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T19:46:38Z","timestamp":1565120798000},"page":"104569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Antibody-based therapies for Huntington\u2019s disease: current status and future directions"],"prefix":"10.1016","volume":"132","author":[{"given":"H\u00e9l\u00e8na L.","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2019.104569_bb0005","author":"AFFITOPE\u00ae PD01A"},{"key":"10.1016\/j.nbd.2019.104569_bb0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pharmtox-010617-052745","article-title":"Toward therapy of human prion diseases","volume":"58","author":"Aguzzi","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.nbd.2019.104569_bb0015","first-page":"7120753","article-title":"An Intrabody Drug (rAAV6-INT41) reduces the binding of N-terminal Huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6\/2 animal model","volume":"2016","author":"Amaro","year":"2016","journal-title":"J. Neurodegener. Dis."},{"key":"10.1016\/j.nbd.2019.104569_bb0020","author":"Antibody platform - Evotec"},{"key":"10.1016\/j.nbd.2019.104569_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington\u2019s disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0030","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104569_bb0035","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molcel.2018.07.032","article-title":"mHTT seeding activity: a marker of disease progression and neurotoxicity in models of Huntington\u2019s disease","volume":"71","author":"Ast","year":"2018","journal-title":"Mol. Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0040","doi-asserted-by":"crossref","first-page":"E5427","DOI":"10.1073\/pnas.1516217112","article-title":"Transcellular spreading of huntingtin aggregates in the Drosophila brain","volume":"112","author":"Babcock","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0045","doi-asserted-by":"crossref","first-page":"7613","DOI":"10.4049\/jimmunol.0803366","article-title":"Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice","volume":"182","author":"Bach","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.nbd.2019.104569_bb0050","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1468-1331.2008.02173.x","article-title":"Cardiovagal modulation upon postural change is altered in Huntington\u2019s disease","volume":"15","author":"B\u00e4r","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0055","series-title":"Antibody-based Targeting of Mutant Huntingtin for the Treatment of Huntington\u2019s Disease. CHDI\u2019s 12th Annual HD Therapeutics Conference. Malta","author":"Bartl","year":"2017"},{"key":"10.1016\/j.nbd.2019.104569_bb0060","series-title":"Targeting Extracellular Mutant Huntingtin With Monoclonal Antibodies","author":"Bartl","year":"2019"},{"key":"10.1016\/j.nbd.2019.104569_bb0065","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(03)13304-1","article-title":"Huntingtin aggregation and toxicity in Huntington\u2019s disease","volume":"361","author":"Bates","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2019.104569_bb0070","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","article-title":"Impairment of the ubiquitin-proteasome system by protein aggregation","volume":"292","author":"Bence","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104569_bb0075","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00401-010-0705-y","article-title":"Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer\u2019s disease","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104569_bb0085","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1038\/s41598-019-44151-0","article-title":"Molecular mechanisms of heterogeneous oligomerization of huntingtin proteins","volume":"9","author":"Bonfanti","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104569_bb0090","doi-asserted-by":"crossref","first-page":"18259","DOI":"10.1523\/JNEUROSCI.4008-12.2012","article-title":"Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington\u2019s disease","volume":"32","author":"Bouchard","year":"2012","journal-title":"J. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.nbd.2019.104569_bb0095","first-page":"II3","article-title":"Pathoanatomy of Parkinson\u2019s disease","volume":"247","author":"Braak","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2019.104569_bb0105","doi-asserted-by":"crossref","first-page":"11437","DOI":"10.1523\/JNEUROSCI.2436-06.2006","article-title":"Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer\u2019s mice overproducing transforming growth factor-beta 1","volume":"26","author":"Buckwalter","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029199","article-title":"Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments","volume":"6","author":"Butler","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0115","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pneurobio.2011.11.004","article-title":"Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins","volume":"97","author":"Butler","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104569_bb0120","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.molmed.2008.07.004","article-title":"The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases","volume":"14","author":"Cardinale","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018296","article-title":"Chronic intranasal treatment with an anti-A\u03b2(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease","volume":"6","author":"Cattepoel","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.tcb.2009.01.005","article-title":"Huntingtin as an essential integrator of intracellular vesicular trafficking","volume":"19","author":"Caviston","year":"2009","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.nbd.2019.104569_bb0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.nbd.2011.10.014","article-title":"Pathological correlates of gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"46","author":"Cersosimo","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104569_bb0140","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1073\/pnas.1702237114","article-title":"Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington\u2019s disease","volume":"114","author":"Chen","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0145","doi-asserted-by":"crossref","first-page":"15197","DOI":"10.1021\/jacs.6b08665","article-title":"The aggregation free energy landscapes of polyglutamine repeats","volume":"138","author":"Chen","year":"2016","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.nbd.2019.104569_bb0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.05229.x","article-title":"Lewy body pathology in fetal grafts","volume":"1184","author":"Chu","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.nbd.2019.104569_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0160","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/brain\/awx255","article-title":"Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease","volume":"140","author":"Cisbani","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104569_bb0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/acn3.730","article-title":"Anti-PrPC antibody rescues cognition and synapses in transgenic alzheimer mice","volume":"6","author":"Cox","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0227-5","article-title":"Tau passive immunization inhibits not only tau but also A\u03b2 pathology","volume":"9","author":"Dai","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.104569_bb0175","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0180","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1523\/JNEUROSCI.4672-12.2013","article-title":"Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer\u2019s disease: prelude to a clinical trial","volume":"33","author":"Davtyan","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0185","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","article-title":"Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length","volume":"22","author":"de Almeida","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0190","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/s41380-018-0021-9","article-title":"Are immunotherapies for Huntington\u2019s disease a realistic option?","volume":"24","author":"Denis","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.nbd.2019.104569_bb2000","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.nbd.2011.10.026","article-title":"Olfaction in Parkinson\u2019s disease and related disorders","volume":"46","author":"Doty","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2019.104569_bb0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood-brain barrier impairments in Huntington\u2019s disease: potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0200","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1073\/pnas.0604547103","article-title":"Flanking sequences profoundly alter polyglutamine toxicity in yeast","volume":"103","author":"Duennwald","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104569_bb0210","doi-asserted-by":"crossref","first-page":"10349","DOI":"10.1523\/JNEUROSCI.3829-06.2006","article-title":"Disease-modifying pathways in neurodegeneration","volume":"26","author":"Finkbeiner","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0220","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of Genetic Factors that modify clinical onset of Huntington\u2019s disease","volume":"162","author":"GeM-HD Consortium","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0225","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nbt.2782","article-title":"The promise and challenge of high-throughput sequencing of the antibody repertoire","volume":"32","author":"Georgiou","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.nbd.2019.104569_bb0230","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","article-title":"Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis","volume":"67","author":"Godin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104569_bb0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.neuroscience.2008.02.051","article-title":"High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice","volume":"153","author":"Go\u00f1i","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2019.104569_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/alzrt272","article-title":"Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer\u2019s disease immunotherapeutics","volume":"6","author":"Goure","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.104569_bb0245","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/brain\/aww021","article-title":"Is Huntington\u2019s disease a tauopathy?","volume":"139","author":"Gratuze","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104569_bb0250","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/WNR.0b013e328358a044","article-title":"Short amyloid-\u03b2 immunogens with spacer-enhanced immunogenicity without junctional epitopes for Alzheimer\u2019s disease immunotherapy","volume":"23","author":"Guan","year":"2012","journal-title":"NeuroReport"},{"key":"10.1016\/j.nbd.2019.104569_bb0255","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington\u2019s disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104569_bb0260","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1523\/JNEUROSCI.19-07-02522.1999","article-title":"Nuclear and neuropil aggregates in Huntington\u2019s disease: relationship to neuropathology","volume":"19","author":"Gutekunst","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0265","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1007\/s00415-014-7403-y","article-title":"Cerebral microbleeds in patients with Parkinson\u2019s disease","volume":"261","author":"Ham","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0270","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.1063093","article-title":"Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies","volume":"294","author":"Heppner","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104569_bb0275","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2019.104569_bb0280","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1093\/nar\/19.15.4133","article-title":"Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains","volume":"19","author":"Hoogenboom","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.nbd.2019.104569_bb0285","article-title":"Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound","volume":"8","author":"Hsu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0290","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1023\/B:SCAM.0000007124.19463.e5","article-title":"Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins","volume":"24","author":"Huang","year":"1998","journal-title":"Somat. Cell Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0295","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0300","author":"ImmuenoPrecise Antibodies LTD"},{"key":"10.1016\/j.nbd.2019.104569_bb0305","author":"Inacio"},{"key":"10.1016\/j.nbd.2019.104569_bb0310","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","article-title":"Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release","volume":"10","author":"Jana","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0315","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of prx002\/rg7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0320","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","article-title":"Human-to-mouse prion-like propagation of mutant huntingtin protein","volume":"132","author":"Jeon","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104569_bb0325","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1073\/pnas.022631799","article-title":"Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity","volume":"99","author":"Khoshnan","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0330","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5607\/en.2017.26.6.321","article-title":"Cell-to-cell transmission of polyglutamine aggregates in C. elegans","volume":"26","author":"Kim","year":"2017","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104569_bb0335","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1093\/hmg\/ddy141","article-title":"Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin","volume":"27","author":"Ko","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0340","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body\u2013like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005727","article-title":"Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity","volume":"4","author":"Kvam","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035241","article-title":"Iron accumulation in deep cortical layers accounts for MRI signal abnormalities in ALS: correlating 7 tesla MRI and pathology","volume":"7","author":"Kwan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0355","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1523\/JNEUROSCI.4846-11.2012","article-title":"Bone marrow transplantation confers modest benefits in mouse models of Huntington\u2019s disease","volume":"32","author":"Kwan","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0360","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.1073\/pnas.071058398","article-title":"Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington\u2019s disease","volume":"98","author":"Lecerf","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0365","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.febslet.2005.03.070","article-title":"Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer\u2019s amyloidosis","volume":"579","author":"Lee","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2019.104569_bb0370","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/ana.20592","article-title":"Abeta42 immunization in Alzheimer\u2019s disease generates Abeta N-terminal antibodies","volume":"58","author":"Lee","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0375","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1074\/jbc.M511018200","article-title":"Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice","volume":"281","author":"Lee","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2019.104569_bb0380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","article-title":"Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model","volume":"116","author":"Levites","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104569_bb0385","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0390","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s11481-011-9329-9","article-title":"Chronological age impacts immunotherapy and monocyte uptake independent of amyloid load","volume":"7","author":"Li","year":"2012","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.nbd.2019.104569_bb0395","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jasms.2007.04.012","article-title":"Mapping the human plasma proteome by SCX-LC-IMS-MS","volume":"18","author":"Liu","year":"2007","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.nbd.2019.104569_bb0400","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1523\/JNEUROSCI.5924-12.2013","article-title":"MER5101, a novel A\u03b21-15:DT conjugate vaccine, generates a robust anti-A\u03b2 antibody response and attenuates A\u03b2 pathology and cognitive deficits in APPswe\/PS1\u0394E9 transgenic mice","volume":"33","author":"Liu","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.104569_bb0410","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104569_bb0415","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","article-title":"Intracerebral inoculation of pathological \u03b1-synuclein initiates a rapidly progressive neurodegenerative \u03b1-synucleinopathy in mice","volume":"209","author":"Luk","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0420","first-page":"395","article-title":"Huntingtin is a scaffolding protein in the ATM oxidative DNA damage response complex","volume":"26","author":"Maiuri","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0425","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/icb.2010.134","article-title":"A multimeric immunogen for the induction of immune memory to beta-amyloid","volume":"89","author":"Mantile","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.nbd.2019.104569_bb0430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0022-2836(91)90498-U","article-title":"By-passing immunization human antibodies from V-gene libraries displayed on phage","volume":"222","author":"Marks","year":"1991","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104569_bb0435","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fnins.2017.00647","article-title":"The evidence for the spread and seeding capacities of the mutant huntingtin protein in in vitro systems and their therapeutic implications","volume":"11","author":"Masnata","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0440","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-019-01973-6","article-title":"Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms","author":"Masnata","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104569_bb0445","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104569_bb0450","doi-asserted-by":"crossref","first-page":"9455","DOI":"10.1523\/JNEUROSCI.4699-13.2014","article-title":"Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits","volume":"34","author":"McKinstry","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0455","author":"Mel\u00e3o"},{"key":"10.1016\/j.nbd.2019.104569_bb0460","first-page":"217","article-title":"Role of different alpha-synuclein strains in synucleinopathies similarities with other neurodegenerative diseases","volume":"5","author":"Melki","year":"2015","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.nbd.2019.104569_bb0465","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.nbd.2019.104569_bb0470","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1523\/JNEUROSCI.0146-10.2010","article-title":"Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington\u2019s disease molecular pathogenesis","volume":"30","author":"Miller","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0475","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2967\/jnumed.107.045385","article-title":"Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer\u2019s disease, and other dementias","volume":"49","author":"Mosconi","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0480","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0485","author":"Nebula Antibody Platform - Immune Biosolutions"},{"key":"10.1016\/j.nbd.2019.104569_bb0490","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrn2995","article-title":"Engaging neuroscience to advance translational research in brain barrier biology","volume":"12","author":"Neuwelt","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0495","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nm840","article-title":"Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report","volume":"9","author":"Nicoll","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0500","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4939-9139-6_10","article-title":"MRI-guided focused ultrasound for targeted delivery of rAAV to the brain","volume":"1950","author":"Noroozian","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104569_bb0505","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104569_bb0510","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/imm.12838","article-title":"Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering","volume":"153","author":"Parola","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.nbd.2019.104569_bb0515","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"\u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2019.104569_bb0520","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/BF03401886","article-title":"Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease","volume":"1","author":"Perutz","year":"1995","journal-title":"Mol. Med."},{"key":"10.1016\/j.nbd.2019.104569_bb0525","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1742-2094-5-42","article-title":"Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice","volume":"5","author":"Petrushina","year":"2008","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.nbd.2019.104569_bb0530","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2010.08.003","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"17","author":"Pfeiffer","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nbd.2019.104569_bb0535","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI123931","article-title":"Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology","volume":"129","author":"Pozzi","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104569_bb0540","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13195-018-0447-y","article-title":"SAR228810: an antibody for protofibrillar amyloid \u03b2 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)","volume":"10","author":"Pradier","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.nbd.2019.104569_bb0545","author":"ProMIS Neurosciences"},{"key":"10.1016\/j.nbd.2019.104569_bb0550","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for \u03b1-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0555","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0560","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1093\/hmg\/ddv335","article-title":"Transcriptional dysregulation of inflammatory\/immune pathways after active vaccination against Huntington\u2019s disease","volume":"24","author":"Ramsingh","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0565","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1093\/hmg\/ddg305","article-title":"Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum","volume":"12","author":"R\u00e9gulier","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0570","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/B978-0-12-381328-2.00014-6","article-title":"Genetics and neuropathology of Huntington\u2019s disease","volume":"98","author":"Reiner","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.nbd.2019.104569_bb0575","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fneur.2017.00037","article-title":"Exploring Braak\u2019s Hypothesis of Parkinson\u2019s Disease","volume":"8","author":"Rietdijk","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0580","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1523\/JNEUROSCI.20-10-03705.2000","article-title":"Wild-type huntingtin protects from apoptosis upstream of caspase-3","volume":"20","author":"Rigamonti","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0585","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004917","article-title":"Dendritic cell-mediated-immunization with xenogenic PrP and adenoviral vectors breaks tolerance and prolongs mice survival against experimental scrapie","volume":"4","author":"Rosset","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104569_bb0590","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15548627.2015.1039219","article-title":"HTT\/Huntingtin in selective autophagy and Huntington disease: A foe or a friend within?","volume":"11","author":"Rui","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.nbd.2019.104569_bb0595","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington\u2019s disease","volume":"103","author":"Ryu","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0600","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"NEJM"},{"key":"10.1016\/j.nbd.2019.104569_bb0605","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","article-title":"Huntington\u2019s disease: the current state of research with peripheral tissues","volume":"219","author":"Sassone","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0610","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104569_bb0615","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.26878","article-title":"First-in-human assessment of PRX002, an anti-\u03b1-synuclein monoclonal antibody, in healthy volunteers","volume":"32","author":"Schenk","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104569_bb0620","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0092-8674(00)80514-0","article-title":"Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo","volume":"90","author":"Scherzinger","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0625","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/ana.25107","article-title":"Mutant huntingtin protein expression and blood-spinal cord barrier dysfunction in huntington disease","volume":"82","author":"Sciacca","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0630","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-6273(01)00177-5","article-title":"Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases","volume":"29","author":"Sherman","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2019.104569_bb0635","doi-asserted-by":"crossref","first-page":"11402","DOI":"10.1073\/pnas.0503634102","article-title":"Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions","volume":"102","author":"Slow","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0640","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.nbd.2019.104569_bb0645","series-title":"Passive Treatment With Huntingtin (Htt)-Specific Mab\u2019s Lowers Htt Levels And Improves Motor Performance In Yac128 Mice","first-page":"1128","author":"Smrzka","year":"2016"},{"key":"10.1016\/j.nbd.2019.104569_bb0650","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/NEN.0b013e3181f530ec","article-title":"Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6\/1 mice","volume":"69","author":"Snyder-Keller","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0655","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/1521-4141(200108)31:8<2338::AID-IMMU2338>3.0.CO;2-V","article-title":"Modulation of proteinase-K resistant prion protein by prion peptide immunization","volume":"31","author":"Souan","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.nbd.2019.104569_bb0660","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1523\/JNEUROSCI.2747-08.2008","article-title":"Intrabodies binding the proline-rich domains of mutant Huntingtin increase its turnover and reduce neurotoxicity","volume":"28","author":"Southwell","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0665","doi-asserted-by":"crossref","first-page":"13589","DOI":"10.1523\/JNEUROSCI.4286-09.2009","article-title":"Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington\u2019s disease","volume":"29","author":"Southwell","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0670","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-synuclein in filamentous inclusions of lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0675","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/brain\/awg077","article-title":"Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course","volume":"126","author":"Squitieri","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104569_bb0680","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00401-015-1518-9","article-title":"Immunotherapies in Alzheimer\u2019s disease: Too much, too little, too late or off-target?","volume":"131","author":"St-Amour","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104569_bb0685","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0690","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0b013e318282514e","article-title":"Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease","volume":"80","author":"St\u00fcwe","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2019.104569_bb0695","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","author":"Tabrizi","year":"2019","journal-title":"NEJM."},{"key":"10.1016\/j.nbd.2019.104569_bb0700","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/nmt.12.34","article-title":"Monitoring Huntington\u2019s disease progression through preclinical and early stages","volume":"2","author":"Tang","year":"2012","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.nbd.2019.104569_bb0705","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0710","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.nbd.2019.104569_bb0715","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/brain\/awr298","article-title":"Blood-brain barrier P-glycoprotein function in Alzheimer\u2019s disease","volume":"135","author":"van Assema","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104569_bb0720","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.arr.2019.01.012","article-title":"The prion-like spreading of \u03b1-synuclein: from in vitro to in vivo models of Parkinson\u2019s disease","volume":"50","author":"Vargas","year":"2019","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.nbd.2019.104569_bb0725","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1097-2765(04)00151-0","article-title":"Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins","volume":"14","author":"Venkatraman","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.nbd.2019.104569_bb0730","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-007-0306-6","article-title":"Huntington disease models and human neuropathology: similarities and differences","volume":"115","author":"Vonsattel","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2019.104569_bb0735","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/brain\/awv107","article-title":"The role of tau in the pathological process and clinical expression of Huntington\u2019s disease","volume":"138","author":"Vuono","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2019.104569_bb0740","author":"VYBION"},{"key":"10.1016\/j.nbd.2019.104569_bb0745","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jmb.2018.03.017","article-title":"Self-assembly of mutant Huntingtin exon-1 fragments into large complex fibrillar structures involves nucleated branching","volume":"430","author":"Wagner","year":"2018","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2019.104569_bb0750","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1172\/JCI64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression","volume":"122","author":"Weiss","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104569_bb0755","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0760","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","article-title":"Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition","volume":"24","author":"Wilcock","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104569_bb0765","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.neuroscience.2006.10.020","article-title":"Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid","volume":"144","author":"Wilcock","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2019.104569_bb0770","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1172\/JCI80743","article-title":"Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients","volume":"125","author":"Wild","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104569_bb0775","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.0505321102","article-title":"Suppression of Huntington\u2019s disease pathology in Drosophila by human single-chain Fv antibodies","volume":"102","author":"Wolfgang","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.nbd.2019.104569_bb0780","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2019.104569_bb0785","doi-asserted-by":"crossref","DOI":"10.1002\/ana.25513","article-title":"Target engagement in an Alzheimer Trial: crenezumab Lowers A\u03b2 oligomers in CSF","author":"Yang","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2019.104569_bb0790","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s13311-013-0187-4","article-title":"Developing therapeutic antibodies for neurodegenerative disease","volume":"10","author":"Yu","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nbd.2019.104569_bb0795","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2019.104569_bb0800","doi-asserted-by":"crossref","first-page":"36631","DOI":"10.1038\/srep36631","article-title":"A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses","volume":"6","author":"Zha","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2019.104569_bb0805","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-12-385883-2.00010-2","article-title":"Huntington disease and the huntingtin protein","volume":"107","author":"Zheng","year":"2012","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.nbd.2019.104569_bb0810","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3389\/fphys.2014.00380","article-title":"Skeletal muscle pathology in Huntington\u2019s disease","volume":"5","author":"Zielonka","year":"2014","journal-title":"Front. Physiol."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119302372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119302372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:16:54Z","timestamp":1760851014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996119302372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":163,"alternative-id":["S0969996119302372"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104569","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody-based therapies for Huntington\u2019s disease: current status and future directions","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104569"}}